Ovid Therapeutics (NASDAQ:IVID) announced a $60 million private placement to fund the expansion of its clinical pipeline into tuberous sclerosis complex seizures and infantile spasms.
The strategic move is bolstered by newly released safety and pharmacokinetic data for the company's lead asset, OV329.
The biopharmaceutical company reported that the 7-milligram dose of OV329 demonstrated a favorable profile supporting its selection for advanced trials, positioning the compound as a potential best-in-category therapy.
Armed with this data, Ovid plans to initiate Phase 2 trials for OV329 in the second quarter of 2026.
Concurrently, the firm announced regulatory clearance to proceed with Phase 1 clinical testing for another pipeline candidate, OV4071, in Australia.
On the financial front, Ovid ended the 2025 fiscal year holding $90.4 million in cash.
The recent $60 million capital injection, combined with an additional $53.9 million in potential proceeds from the exercise of Series A warrants, provides the company with a significantly strengthened balance sheet.
Management indicated that these combined capital resources have the potential to extend the company's operational runway into 2029, securing necessary financing through multiple critical clinical milestones.